Replimune (NASDAQ: REPL) CCO sells 6,500 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Replimune Group, Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock in an open-market transaction. The shares were sold on April 2, 2026 at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance. After this sale, Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units, and holds options to acquire an additional 250,425 shares, 142,555 of which are currently exercisable.

Insights

Small, pre-planned stock sale by Replimune’s CCO looks routine.

Chief Commercial Officer Christopher Sarchi sold 6,500 Replimune shares at a weighted average of $8.01 per share in an open-market transaction on April 2, 2026. This is a modest sale relative to his remaining equity exposure.

The transaction occurred under a Rule 10b5-1 trading plan adopted on December 15, 2025, suggesting it was scheduled independent of short-term news. After the sale, he still beneficially owns 151,588 shares and holds options for 250,425 shares, 142,555 currently exercisable, leaving substantial aligned equity incentives.

Insider Trade Summary 10b5-1

Net Seller: 6,500 shares ($52,065)

Net Sell 1 txn

Insider Sarchi Christopher

Role Chief Commercial Officer

Sold 6,500 shs ($52K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,500	$8.01	$52K

Holdings After Transaction: Common Stock — 151,588 shares (Direct)

Footnotes (1)

The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this Form 4, the reporting person continues to beneficially own 151,588 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 250,425 shares of the Issuer's common stock, 142,555 of which are exercisable as of the date hereof.

Key Figures

Shares sold: 6,500 shares Weighted average sale price: $8.01 per share Shares owned after sale: 151,588 shares +3 more

6 metrics

Shares sold 6,500 shares Open-market sale on April 2, 2026

Weighted average sale price $8.01 per share Common stock sale range $8.00–$8.06

Shares owned after sale 151,588 shares Beneficial ownership including restricted stock units

Stock options held 250,425 options Options to acquire Replimune common stock

Exercisable options 142,555 options Portion of options exercisable as of reporting date

Rule 10b5-1 plan adoption date December 15, 2025 Plan governing the reported stock sale

Key Terms

Rule 10b5-1(c), weighted average price, restricted stock units, options to acquire, +1 more

5 terms

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported reflects a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units financial

"beneficially own 151,588 shares of the Issuer's common stock, including restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

options to acquire financial

"The reporting person also holds options to acquire an aggregate of 250,425 shares"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/06/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sarchi Christopher

(Last)

(First)

(Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN

MASSACHUSETTS

01801

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/02/2026		S⁽¹⁾		6,500	D	$8.01⁽²⁾	151,588⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Following the sales reported on this Form 4, the reporting person continues to beneficially own 151,588 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 250,425 shares of the Issuer's common stock, 142,555 of which are exercisable as of the date hereof.

	/s/ Shawn Glidden, attorney-in-fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Replimune (REPL) executive Christopher Sarchi report in this Form 4?

Christopher Sarchi, Replimune’s Chief Commercial Officer, reported selling 6,500 shares of common stock. The open-market sale occurred at a weighted average price of $8.01 per share, with trades executed between $8.00 and $8.06 on April 2, 2026.

At what price did Replimune (REPL) shares sell in Sarchi’s latest transaction?

The reported sale used a weighted average price of $8.01 per share. Individual trades were executed in multiple transactions within a price range from $8.00 to $8.06, as disclosed in the weighted-average pricing footnote to the Form 4 filing.

Was the Replimune (REPL) insider sale under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sales were made under a trading plan adopted on December 15, 2025, intended to comply with Rule 10b5-1(c). Such plans pre-schedule trades, reducing the significance of short-term market timing by the insider.

How many Replimune (REPL) shares does Christopher Sarchi still beneficially own after this sale?

Following the reported sale, Christopher Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units. This remaining position shows he retains a meaningful direct equity stake in the company after the 6,500-share disposition.

What stock options does Replimune (REPL) executive Christopher Sarchi hold according to the Form 4?

The filing notes that Sarchi holds options to acquire 250,425 shares of Replimune common stock. Of this total, 142,555 options are exercisable as of the reporting date, representing significant additional potential equity exposure beyond his current share holdings.

How large is the reported Replimune (REPL) insider sale relative to Sarchi’s remaining holdings?

The transaction involved selling 6,500 shares, while Sarchi continues to beneficially own 151,588 shares plus options for 250,425 shares. This indicates the sale represents only a small portion of his overall direct and option-based Replimune equity exposure.